| Pam Ramirez, RN | |
|
415 Us Highway 95a S, Ste I 901, Fernley, NV 89408-9261 | |
| (775) 575-7744 | |
| (775) 575-7769 |
| Full Name | Pam Ramirez |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Psychiatric/mental Health |
| Location | 415 Us Highway 95a S, Fernley, Nevada |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679883805 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WP0808X | Registered Nurse - Psychiatric/mental Health | RN66498 (Nevada) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Pam Ramirez, RN 1665 Old Hot Springs Rd, Ste 157, Carson City, NV 89706-0782 Ph: (775) 687-5162 | Pam Ramirez, RN 415 Us Highway 95a S, Ste I 901, Fernley, NV 89408-9261 Ph: (775) 575-7744 |
News Archive
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that, on June 1, 2010, the Company received a letter from The Nasdaq Stock Market indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, Nile was not in compliance with Marketplace Rule 5550(a)(2).
Syneron Medical Ltd., a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.
Nuclear engineers at Oregon State University have developed a small, portable and inexpensive radiation detection device that should help people all over the world better understand the radiation around them, its type and intensity, and whether or not it poses a health risk.
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.
› Verified 8 days ago
Mrs. Cassandra Jo Peat, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 555 E Main St, Fernley, NV 89408 Phone: 775-575-3363 Fax: 775-575-3364 | |
Julie Marie Dums, R.N. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 555 E Main St, Fernley, NV 89408 Phone: 775-575-3363 Fax: 775-575-3364 | |
Jackie Chapman, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 415 Highway 95a, Building I, Fernley, NV 89408 Phone: 775-575-7744 Fax: 775-575-7767 |